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a  b  s  t  r  a  c  t
Pneumococcal  disease  is a major  cause  of  morbidity  and  mortality  in  young  children,  particularly  in  the
developing  world.  Vaccines  are  a critical  strategy  for protecting  children  from  pneumococcal  disease  and
licensed  pneumococcal  conjugate  vaccines  (PCVs)  are  having  a signiﬁcant  impact  on  invasive  pneumo-
coccal  disease  and  pneumococcal  pneumonia  throughout  the world.  Currently  available  PCVs  do  not,
however,  cover  all pneumococcal  serotypes  and  are  complicated  and  relatively  expensive  to  manufac-asopharyngeal carriage
rotein vaccine
nfant vaccination
ture. While  new  PCV development  is  focused  on either  higher  valency  or more  inherent  affordability
for  developing  countries,  new  vaccines  are  needed  that  offer  serotype-independent  protection.  Vaccines
containing  proteins  that  are  common  to all  pneumococcal  serotypes  could  provide  broad  protection  to
children worldwide.  Protein  subunit  and  whole  cell  vaccines  have  advanced  into  Phase  1  and  2  clinical
trials  but  face considerable  challenges  before  they  can become  licensed  and  widely  distributed.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CCPneumonia remains the leading global cause of death among
hildren under age ﬁve, killing more than 900,000 children in 2013
nd accounting for 15% of all child deaths [1]. Streptococcus pneu-
oniae (pneumococcus), the bacterium that is the most common
ause of severe pneumonia, kills a half million children annually
efore their ﬁfth birthday [2]. Pneumococcus also causes sepsis
nd meningitis and is one of the leading causes of bacterial otitis
edia (OM). In addition, pneumococcus causes signiﬁcant morbid-
ty and mortality in elderly adults [3]. Vaccines are a critical strategy
or protecting children from pneumococcal diseases, particularly in
frica and Asia, where 95% of all pneumococcal deaths occur [5].
neumococcus has more than 90 serotypes, which vary by region.
urrently licensed pneumococcal conjugate vaccines (PCVs) are
ffective, but protection is limited to pneumococcal disease caused
y serotypes contained in the vaccines.
Invasive pneumococcal disease (IPD) is diagnosed by culture
f pneumococcus from normally sterile sites, such as blood or
erebrospinal ﬂuid. The majority of pneumococcal pneumonia,
owever, is difﬁcult to diagnose because most cases are blood
ulture negative. A number of new diagnostic assays are in devel-
pment, including molecular- and urine-based antigen tests. As
neumococci are transmitted by direct contact with respiratory
ecretions from patients and healthy carriers [4], it is important
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to differentiate disease from asymptomatic nasopharyngeal (NP)
carriage in young children. Pneumococcal disease is treated with
antimicrobials; however a number of pneumococcal strains have
become resistant to ﬁrst line antibiotics. Macrolide resistance has
increased in many parts of the world and multidrug resistance
has become a serious concern in the treatment of IPD, especially
in Asian countries [6]. With the success of PCVs, however, fewer
antibiotic-resistant pneumococcal infections are being reported
since they tend to be the serotypes covered by the licensed vaccines.
1. Currently available vaccines and their limitations
Antibodies to the capsular polysaccharides on pneumococci are
protective. Licensed PCVs are based on formulations of various
capsular antigens derived from the selected serotypes. Successful
vaccination in pediatric populations has been achieved by conju-
gating the polysaccharides to carrier proteins, which vary between
manufacturers. In 2007, the WHO  recommended the use of PCVs in
all countries, setting highest priority for countries with high pneu-
monia and mortality rates in children less than ﬁve years of age
[7]. Two licensed, WHO-prequaliﬁed PCVs are currently available:
the 13-valent Prevnar 13® manufactured by Wyeth Pharmaceut-
icals (Pﬁzer) and the 10-valent vaccine Synﬂorix® manufactured
by GlaxoSmithKline Biologicals (GSK). With the help of Gavi, the
Vaccine Alliance, the Advance Market Commitment funding mech-
anism and other international donors, PCVs are being rolled out in
low-income countries.
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Table 1
Development status of current vaccine candidates (POC = proof of concept trial).
Candidate name/identiﬁer (company) Preclinical Phase 1 Phase 2 POC Phase 3
Pneumococcal conjugate vaccines (PCVs)
15 valent PCV (Merck & Co.) X
12  valent PCV (GlaxoSmithKline [GSK]) X
10  valent PCV (Panacea Biotech, Ltd.) X
10  valent PCV (Serum Institute of India, Ltd.) X
Multivalent PCV (SK Chemicals and Sanoﬁ Pasteur) X
Multivalent PCV (Pnuvax) X
Common protein vaccines
Pneumococcal whole cell vaccine (PATH/Boston Children’s Hospital) X
PhtD/pneumolysoid/PcpA common protein vaccine (Sanoﬁ Pasteur) X
Trivalent protein (Genocea Biosciences) X
Two  or more pneumococcal proteins loaded on bacterium-like-particles (Mucosis B.V.) X
Live  Recombinant Attenuated Salmonella Vaccine (Arizona State University) X










































APhtD/pneumolysoid common protein vaccine (GSK) 
Particle based PCV (Liquidia Technologies) 
Novel conjugation technology using common protein carriers (Afﬁnivax, Inc.) 
Prevnar 13® and Synﬂorix® are effective against vaccine
erotypes but do not protect against all 90 plus pneumococ-
al serotypes. Despite a clear overall beneﬁt of PCVs, increasing
neumococcal disease caused by non-vaccine serotypes, through
erotype emergence or replacement, in high-income countries has
een documented and may  limit the overall beneﬁt of PCVs [8].
his may  be particularly relevant for low-income countries where
here is a broader spectrum of serotypes that cause disease. Fur-
hermore, PCVs are difﬁcult to produce and relatively expensive
s a result, which, without considerable ﬁnancial assistance, lim-
ts their affordability and accessibility for low-income countries.
herefore, new vaccines are needed that are more affordable and
rovide either focused protection for children against serotypes
revalent in the developing world or, ideally, broad protection
cross all pneumococcal serotypes.
. General approaches to vaccine development for low- and
iddle-income country markets
A number of approaches are being pursued to develop safe,
ffordable and effective vaccines against pneumococcal disease
or children in the developing world. One such approach focuses
n PCVs that protect against the most common serotypes causing
PD in low-income countries. Manufacturing processes are being
esigned to incorporate more efﬁcient methods for fermenting and
urifying polysaccharides, producing carrier proteins, conjugating
olysaccharides to carrier proteins, and packaging vaccines into
ulti-dose vials, thereby reducing overall costs. Other strategies
nclude targeting conserved surface epitopes common to most or
ll pneumococcal strains. A new generation of vaccines is targeting
ommon proteins including, but not limited to, pneumolysin,
neumococcal surface protein A (PspA), pneumococcal surface
rotein C (PspC), pneumococcal surface antigen A (PsaA), neu-
aminidase enzymes, and histidine-triad proteins, with the aim
f inducing broader cross-serotype protection than current PCVs.
n addition, potentially low-cost, vector-based technologies are
llowing for the expression of pneumococcal proteins in attenu-
ted Salmonella strains. Preclinical studies have demonstrated that
accines based on common pneumococcal proteins can protect
ice from NP carriage, pneumonia, and IPD after challenge with S.
neumoniae. The most advanced protein vaccine candidates have
een tested clinically, including Phase 2 trials in infants and young
hildren. Clinical data will be forthcoming over the next few years
egarding the ability of protein vaccines to protect against NP
arriage, OM,  lower respiratory tract infections, and pneumonia.
dditional strategies that also hold promise for enabling low-costX
X
X
and broadly protective vaccines include inactivated whole cell
preparations and vaccines that combine protein and conjugate
technologies. The latter approach involves either the addition of
proteins to an existing PCV or the use of common pneumococcal
proteins as the carrier for a PCV. To be deemed successful, protein
subunit vaccines must demonstrate equivalence with licensed
vaccines in their ability to reduce both pneumococcal disease and
NP carriage rates, which will in turn confer greater herd immunity.
Protein vaccines that impact disease but not NP carriage would
likely be used in conjunction with PCVs (Table 1).
3. Technical and regulatory assessment
The ﬁrst PCV—the 7-valent Prevnar®—was licensed in 2000
based upon data from a large US clinical trial that showed efﬁ-
cacy against IPD. Incidence of IPD overall and for PCV-7-serotypes
declined by 45% and 94%, respectively [9]. Rates of pneumonia and
OM also decreased. The WHO  developed recommendations for the
production and control of PCVs to provide licensure criteria for new
PCVs [10]. Second-generation PCVs—including Synﬂorix® and Pre-
vnar 13®—were licensed on the basis of non-inferiority to PCV-7 in
immunogenicity studies rather than efﬁcacy trials. Immunogenic-
ity was assessed by serotype-speciﬁc immunoglobulin G antibody
concentrations as measured by enzyme-linked immunosorbent
assay and functional antibody levels as measured by opsonophago-
cytic assay. Other PCVs in development will likely follow the same
licensure pathway used by Synﬂorix® and Prevnar 13®, except that
they may  be required to use one of these vaccines as a compara-
tor for non-inferiority trials. The protein subunit vaccines under
development face several challenges to licensure. Correlates of pro-
tection capable of predicting clinical beneﬁts may  be necessary
for the licensure of protein vaccines, but are not yet well-deﬁned.
Whether or not a vaccine can be licensed on the basis of its impact
on NP carriage alone and/or OM is unclear. Or would a full pneu-
monia or IPD efﬁcacy trial be needed? Market approval for an OM
indication may  make performing post-marketing studies for pneu-
monia and/or IPD possible. Advancing to WHO  prequaliﬁcation
rapidly once licensure is obtained is critical since the disease burden
is highest in countries with the greatest resource constraints.
4. Status of vaccine R&D activitiesAs noted above, a number of vaccine manufacturers in low
and middle income countries are engaged in the development
of multivalent PCVs. Most of these efforts are at the preclinical
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pproximate currently licensed PCVs in most respects but at a
ower cost [11]. The most advanced candidates that are in clinical
evelopment (Phase 1 and 2 trials) are 10- to 13-valent PCVs being
eveloped by the Serum Institute of India, Ltd., SK Chemical Co.,
nd Panacea Biotech, Ltd.
Other pneumococcal vaccine development efforts are focused
n conserved epitopes on proteins common to all pneumococcus
erotypes. Sanoﬁ Pasteur is developing the most advanced protein-
ubunit vaccine, which comprises the following recombinant
roteins: pneumococcal histidine triad protein D (PhtD), pneumo-
occal choline-binding protein A (PcpA), and pneumolysoid [12].
his trivalent vaccine has completed a Phase 1 age de-escalation
tudy in Bangladesh, demonstrating both safety and immunogenic-
ty. An alternative approach that PATH is pursuing in collaboration
ith Boston Children’s Hospital is an inactivated pneumococcal
hole cell vaccine candidate that may  provide broad protection
nd be inexpensive to produce and administer. This vaccine candi-
ate is intended to protect against both NP carriage and invasive
isease/pneumonia and is currently in a Phase 1/2 age de-escalation
linical trial in Kenya after completing a Phase 1 study in healthy
dults in the United States. Genocea Biosciences is developing a
rivalent protein vaccine intended to protect against NP carriage.
 Phase 1 clinical trial of this product has completed and found
he vaccine candidate to be safe and immunogenic. It is currently
eing assessed for an impact on carriage in an adult experimental
P challenge model.
GSK is developing a bivalent protein vaccine, comprising PhtD
nd pneumolysoid that is designed to add to the protection pro-
ided by PCVs. In collaboration with PATH, the Medical Research
ouncil and the London School of Hygiene and Tropical Medicine,
SK is testing its protein-plus-conjugate vaccine candidate in a
hase 2 clinical trial in The Gambia. Results could shed light on the
otential for protein-based approaches to generate more protective
neumococcal vaccines for young children. In another approach,
iquidia Technologies is using its particle-based technology that
ombines polysaccharides and common proteins in order to mimic
onjugate vaccines. Afﬁnivax is also using its multiple antigen pre-
enting system technology to couple polysaccharides with proteins
13].
. Major advances in last 3–5 years
The licensure of the higher-valency PCVs (10- and 13-valent)
nd their recent introduction into Gavi-eligible countries is begin-
ing to have a signiﬁcant global impact on pneumococcal disease.
accine manufacturers in low- and middle-income countries are
orking to develop and license additional PCVs that would be
vailable at a lower cost than current PCVs. Clinical development
f protein subunit vaccines has advanced considerably, such that
ultiple candidates have entered into Phase 2 trials that include
P carriage in infants as an outcome. Several vaccine developers
ncluding GSK, Sanoﬁ Pasteur, and Genocea are actively advancing
rotein subunit vaccines.
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6. Likelihood for ﬁnancing
Gavi has supported the rollout of Prevnar 13® and Synﬂorix®
in more than 25 countries since 2010. More than 50 countries
have been approved for Gavi support to introduce PCVs into
their national immunization programs. The WHO  recommends
a three-dose schedule for PCVs (either a three-dose schedule in
infants or a two-dose prime-plus-booster dose). The current cost
to Gavi is approximately US $3.10–$3.40 per dose or $9.30–$10.20
per fully vaccinated child. To date, Gavi and its partners have
supported the immunization of more than 10 million children. PCV
procurement represents a large ﬁnancial burden for Gavi and is
responsible for more than 40% of Gavi’s expenditures on vaccines.
Lower cost pneumococcal vaccines, particularly those that could
also increase coverage against pneumococcal serotypes, are of
highest importance.
Conﬂict of interest statement:  None declared.
References
[1] Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional,
and national causes of child mortality in 2000–13, with projections
to  inform post-2015 priorities: an updated systematic analysis. Lancet
2014;385(9966):430–40.
[2] World Health Organization. Estimated Hib and pneumococcal deaths for
children under 5 years of age; 2008. March 2012. http://www.who.int/
immunization monitoring/burden/Pneumo hib estimates/en/index.html
[accessed 21.08.13].
[3] Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease.
Clin Microbiol Infect 2014;(Suppl. 5):45–51.
[4] World Health Organization. http://www.who.int/biologicals/vaccines/
pneumococcal/en/.
[5] O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M,  McCall N, et al.
Burden of disease caused by Streptococcus pneumoniae in children younger than
5  years: global estimates. Lancet 2009;374:893–902.
[6] Song J-H. Advances in pneumococcal antibiotic resistance. Expert Rev Respir
Med  2013;7(5):491–8.
[7] Pneumococcal conjugate vaccine for childhood immunization – WHO  position
paper. Wkly Epidemiol Rec (WER) 2007;82(March (12)):93–104.
[8] Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect
of  the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal
disease in England and Wales 4 years after its introduction: an observational
cohort study. Lancet Infect Dis 2015;15:535–43.
[9] Pilishvili T, Lexau C, Farley MM,  Hadler J, Harrison LH, Bennett NM, et al. Sus-
tained reductions in invasive pneumococcal disease in the era of conjugate
vaccine. J Infect Dis 2010;201(1):32–41.
10] World Health Organization. Recommendations to assure the quality, safety
and  efﬁcacy of pneumococcal conjugate vaccines-proposed replacement of
TRS 927, Annex 2, ECBS, 19–23 October 2009; 2010 http://www.who.int/
biologicals/areas/vaccines/pneumo/Pneumo ﬁnal 23APRIL .pdf.
11] Ginsburg AS, Alderson MR. New conjugate vaccines for the prevention of
pneumococcal disease in developing countries. Drugs Today 2011;47(3):
207–14.
12] Brooks WA,  Chang LJ, Sheng X, Hopfer R, PPR02 Study Team. Safety and
immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumo-controlled study. Vaccine 2015;(July). pii:S0264-410X(15)00879-8.
13] Zhang F, Lu YJ, Malley R. Multiple antigen-presenting system (MAPS) to
induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci U S A
2013;110(August (33)):13564–9.
